Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)

Launched by DR. AMIT DRUYAN · Dec 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Allocetra, which is given directly into the jaw joint to see if it is safe and effective for people with osteoarthritis of the temporomandibular joint (TMJ). Osteoarthritis is a condition that causes pain and stiffness in the joints, and this trial aims to help patients who suffer from discomfort and inflammation in their jaw.

To participate in this study, you need to be between the ages of 18 and 75 and have been diagnosed with TMJ osteoarthritis, along with some specific signs of inflammation seen on an MRI scan. You cannot have had any injections into your jaw joint in the past three months or have had significant injuries or surgeries in that area. Participants will receive the Allocetra treatment and be monitored for any side effects or improvements in their condition. This trial is currently recruiting, so if you think you might be eligible, it could be a good opportunity to explore a new treatment option for your jaw pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with temporomandibular OA in the target TMJ.
• • 2. Inflammatory findings by Magnetic Resonance Imaging (MRI).
• • 3. Acceptable blood workup results (CBC, electrolytes, kidney and liver function).
• Exclusion Criteria:
• • 1. Prior intra-articular injection to the target TMJ within 3 months prior to treatment.
• • 2. Any significant injury or surgery to the target TMJ.
• • 3. Evidence of active local infection in the vicinity of the target TMJ or clinically significant active infection anywhere in the body.
• • 4. Patients with a known neurological disease or rheumatic condition, a major medical condition that would affect quality of life and influence the results of the study, or other pain of unknown etiology.